Trial Profile

A Prospective, Multicenter study to evaluate the efficacy of the salvage therapy with Sofosbuvir, Elbasvir, Grazoprevir and Ribavirin for the treatment of GT3 and GT1/4 HCV Infection in patients who relapsed following DAA treatment including an NS5A inhibitor

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 22 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elbasvir (Primary) ; Grazoprevir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
Indications Hepatitis C
Focus Therapeutic Use

11 Dec 2018 New trial record
13 Nov 2018 Results (n=30) presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com